The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
Open accessAbstract
Significance: This study shows that the telomerase reverse transcriptase ( TERT ) promoter mutations, which create de novo E-twenty six/ternary complex factors (Ets/TCF) transcription binding sites, besides being the most common somatic genetic lesions, influence both survival and disease recurrence in bladder cancer patients. The effect of the TERT promoter mutations on both survival and recurrence is modified by a common polymorphism within the preexisting Ets binding site in the TERT promoter. The data were supported by the results from reporter assays carried out in two urothelial carcinoma cell lines. The findings of the study suggest that the TERT promoter mutations in conjunction with the common polymorphism have potential of being used as clinical biomarkers in bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P., Kassouf, W., Kiemeney, L. A., La Vecchia, C., Shariat, S., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,164
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013) · Science · doi:10.1126/science.1229259 · Cited by 1,816
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 6×
“The core TERT promoter region 343 bp (from the position −278 to +65 from ATG start site) was screened for mutations using PCR and Sanger sequencing (Table S4) as described (7).”
BackgroundMethodInfluentialSelf-citationKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 1×
“The altered pathways in the both variants of bladder cancer have been a subject of research for targeted therapy (17, 18).”
BackgroundDulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 735
Urothelial tumorigenesis: a tale of divergent pathways
Wu, X.-R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1697 · Cited by 692
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo
Wei, G., Badis, G., Berger, M. F., Kivioja, T., Palin, K., Enge, M., Bonke, M., Jolma, A., Varjosalo, M., Gehrke, A. R., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.106 · Cited by 568 · cited 11×
“The somatic mutations specifically create CCGGAA/T binding motifs for Ets/TCF, which are distinct from the preexisting GGAA sites in the TERT promoter.”
BackgroundInfluentialYan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 529
Study, A. C., Bojesen, S. E., Study, A. O. C., Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), (GENICA), G. E. I. A. B. C., (SWE-BRCA), S. B. C. S., The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), (EMBRACE), E. S. O. B. &. B. M. C., (GEMO), G. M. O. C. R. I. B. M. C., Pooley, K. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2566 · Cited by 528
Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers
Kyo, S., Takakura, M., Fujiwara, T., & Inoue, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00878.x · Cited by 347
Novel anticancer therapeutics targeting telomerase
Ruden, M., & Puri, N. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.007 · Cited by 310
Regulation of the human catalytic subunit of telomerase (hTERT)
Daniel, M., Peek, G. W., & Tollefsbol, T. O. (2012) · Gene · doi:10.1016/j.gene.2012.01.095 · Cited by 266
Xu, D., Wang, Q., Gruber, A., Björkholm, M., Chen, Z., Zaid, A., Selivanova, G., Peterson, C., Wiman, K. G., & Pisa, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203890 · Cited by 257
Joudi, F. N., Smith, B. J., & O’Donnell, M. A. (2006) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.11.026 · Cited by 245
Renaud, S., Loukinov, D., Abdullaev, Z., Guilleret, I., Bosman, F. T., Lobanenkov, V., & Benhattar, J. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1125 · Cited by 204
Bladder cancer: translating molecular genetic insights into clinical practice
Cheng, L., Zhang, S., MacLennan, G. T., Williamson, S. R., Lopez-Beltran, A., & Montironi, R. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.07.007 · Cited by 199
Epidemiology and Etiology of Premalignant and Malignant Urothelial Changes
Cohen, S. M., Shirai, T., & Steineck, G. (2000) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590050509869 · Cited by 191
Self-citationEts2 Maintains hTERT Gene Expression and Breast Cancer Cell Proliferation by Interacting with c-Myc
Xu, D., Dwyer, J., He, L., Duan, W., & Liu, J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800790200 · Cited by 143
Have environmental mutagens caused oncomutations in people?
Thilly, W. G. (2003) · Nature Genetics · doi:10.1038/ng1205 · Cited by 137
Urothelial carcinoma of the bladder: definition, treatment and future efforts
Prasad, S. M., DeCastro, G. J., & Steinberg, G. D. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.144 · Cited by 136
Kuball, J. H. E., Wen, S. F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D. C., Grace, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.957 · Cited by 135
Kote‐Jarai, Z., Saunders, E. J., Leongamornlert, D. A., Tymrakiewicz, M., Dadaev, T., Jugurnauth-Little, S., Ross‐Adams, H., Olama, A. A. A., Benlloch, S., Halim, S., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt086 · Cited by 122
Separation of telomerase functions by reverse genetics
Mukherjee, S., Firpo, E. J., Wang, Y., & Roberts, J. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112414108 · Cited by 111
Hsu, C., Hsu, N.-Y., Lee, L., & Ko, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.02.014 · Cited by 94
Stein, G. S., Montecino, M. A., van Wijnen, A. J., Stein, J. L., & Lian, J. B. (2000) · PubMed · Cited by 87
Transcriptional regulation of telomerase activity: Roles of the the Ets transcription factor family
DWYER, J., LI, H., XU, D., & LIU, J. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1396.022 · Cited by 77
Genetic variation in five genes important in telomere biology and risk for breast cancer
Savage, S. A., Chanock, S. J., Lissowska, J., Brinton, L. A., Richesson, D. A., Pepłońska, B., Bardin‐Mikolajczak, A., Zatoński, W. A., Szeszenia‐Dąbrowska, N., & García‐Closas, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603934 · Cited by 76
Beesley, J., Pickett, H. A., Johnatty, S. E., Dunning, A. M., Chen, X., Li, J., Michailidou, K., Lu, Y., Rider, D. N., Weber, R. P., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024987 · Cited by 59
p53 mutations in urinary bladder cancer
Berggren, P., Steineck, G., Adolfsson, J., Hansson, J., JANSSON, O. T., Larsson, P., Sandstedt, B., Wijkström, H., & Hemminki, K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1823 · Cited by 58
Self-citationVaradi, V., Brendle, A., Grzybowska, E. A., Johansson, R., Enquist, K., Butkiewicz, D., Pamuła‐Piłat, J., Pękala, W., Hemminki, K., Lenner, P., et al. (2009) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2008.12.006 · Cited by 36
Self-citationRyk, C., Berggren, P., Kumar, R., Hemminki, K., Larsson, P., Steineck, G., Lambert, B., & Hou, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20650 · Cited by 25
Self-citationPatton, E. E., & Harrington, L. A. (2013) · Nature · doi:10.1038/495320a · Cited by 13
Cited by
Advances in bladder cancer biology and therapy
Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 735
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716
The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566
Role of non-coding sequence variants in cancer
Khurana, E., Fu, Y., Chakravarty, D., Demichelis, F., Rubin, M. A., & Gerstein, M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.17 · Cited by 468
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
Metadata
- Authors
- Rachakonda, P. S., Hosen, I., de Verdier, P. J., Fallah, M., Heidenreich, B., Ryk, C., Wiklund, N. P., Steineck, G., Schadendorf, D., Hemminki, K., & Kumar, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-10-07
- Volume
- 110
- Issue
- 43
- Pages
- 17426-17431
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2008493391
- Cited by
- 340
- References
- 37
- FWCI
- 32.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.